Last ¥5,903 JPY
Change Today +43.00 / 0.73%
Volume 4.5M
4502 On Other Exchanges
As of 1:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - ¥5,970
52 Week Low
10/17/14 - ¥4,338
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and collaboration agreement with Mersana Therapeutics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Launches Treatment for Ethylene Glycol and Methanol Poisonings in Japan

Takeda Pharmaceutical Company Limited has announced the availability of Fomepizole Intravenous Infusion 1.5g Takeda, or fomepizol, for the treatment of ethylene glycol and methanol poisonings in Japan. Fomepizole, an alcohol dehydrogenase inhibitor, is marketed and distributed by Paladin Labs Inc. in Canada and is the standard treatment for ethylene glycol and methanol poisonings.

Takeda Pharmaceutical Company Limited Announces the Start of Phase 2/3 and Phase 3 Clinical Trials of rasagiline

Takeda Pharmaceutical Company Limited announced the start of Phase 2/3 and Phase 3 clinical trials of rasagiline (generic name, development code: TVP-1012), an investigational compound for the treatment of Parkinson's disease, in Japan. The main portion of clinical trials started this time aiming to examine efficacy and safety of rasagiline consists of a couple of multicenter, randomized, double-blind and placebo-controlled parallel-group comparative trials. One is a Phase 2/3 clinical trial conducted with the Japanese patients with Parkinson's disease under the treatment with levodopa (adjunctive therapy study), and its primary endpoint is change of mean total daily off-time. Another is a Phase 3 clinical trial conducted with the Japanese patients with early stage Parkinson’s disease (monotherapy study), and its primary endpoint is sum of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts 2 and 3 scores.

Takeda Pharmaceutical Company Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM

Takeda Pharmaceutical Company Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Christophe Weber, President, Chief Operating Officer and Representative Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,903.00 JPY +43.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.76 USD -0.50
Astellas Pharma Inc ¥1,830 JPY +6.50
Baxter International Inc $70.31 USD -1.07
Becton Dickinson and Co $138.08 USD -2.23
Shire PLC 4,854 GBp -44.00
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings 42.1x
Price/Sales 2.5x
Price/Book 1.8x
Price/Cash Flow 14.0x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at